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A B S T R A C T
Adriamycin is a potent anthracycline-type antitumor agent, but it also exerts potentially serious side eﬀects due
to its cardiotoxic and neurotoxic propensity. Multiple impairments in sensory nerve functions have been recently
reported in various rat models. The present experiments were initiated in an attempt to reveal adriamycin-
induced changes in sensory eﬀector functions of chemosensitive meningeal aﬀerents.
Meningeal blood ﬂow was measured with laser Doppler ﬂowmetry in the parietal dura mater of adult male
Wistar rats. The dura mater was repeatedly stimulated by topical applications of capsaicin, a transient receptor
potential vanilloid 1 (TRPV1) receptor agonist, or acrolein, a transient receptor potential ankyrin 1 (TRPA1)
receptor agonist, which induce the release of calcitonin gene-related peptide (CGRP) from meningeal aﬀerents.
The blood ﬂow increasing eﬀects of CGRP, histamine, acetylcholine and forskolin were also measured.
Capsaicin- and acrolein-induced CGRP release was measured with enzyme-linked immunoassay in an ex vivo
dura mater preparation. TRPV1 content of trigeminal ganglia and TRPV1-, CGRP- and CGRP receptor compo-
nent-immunoreactive structures were examined in dura mater samples obtained from control and adriamycin-
treated rats.
The vasodilator eﬀects of capsaicin, acrolein and CGRP were signiﬁcantly reduced in adriamycin-treated
animals while histamine-, acetylcholine- and forskolin-induced vasodilatation were unaﬀected. Measurements of
CGRP release in an ex vivo dura mater preparation revealed an altered dynamic upon repeated stimulations of
TRPV1 and TRPA1 receptors. In whole-mount dura mater preparations immunohistochemistry revealed altered
CGRP receptor component protein (RCP)-immunoreactivity in adriamycin-treated animals, while CGRP receptor
activity modifying protein (RAMP1)-, TRPV1- and CGRP-immunostaining were left apparently unaltered.
Adriamycin-treatment slightly reduced TRPV1 protein content of trigeminal ganglia.
The present ﬁndings demonstrate that adriamycin-treatment alters the function of the trigeminovascular
system leading to reduced meningeal sensory neurogenic vasodilatation that may aﬀect the local regulatory and
protective mechanisms of chemosensitive aﬀerents leading to alterations in tissue integrity.
1. Introduction
Anthracyclines comprise an important class of chemotherapeutic
agents still indispensable in the treatment of various malignancies
(Carvalho et al., 2009; Kalyanaraman et al., 2002). Adriamycin, despite
its potentially serious side eﬀects, is one of the most commonly used
antracycline derivative for its favorable antineoplastic activity. Besides
its deleterious eﬀects on cardiac muscle resulting in congestive cardi-
omyopathy, adriamycin exerts neurotoxic eﬀects on primary sensory
neurons in experimental animals and also in man (Bigotte and Olsson,
1982; Katona et al., 2004; Kondo et al., 1987; Minow and Gottlieb,
1975). Recent studies demonstrated marked structural, neurochemical
and functional impairments of primary sensory neurons in animal
models of adriamycin toxicity (El-Agamy et al., 2017; Kosoko et al.,
2017). Neurotoxic propensity of adriamycin manifests as deleterious
actions on chemosensitive sensory neurons which express transient
receptor potential nociceptive ion channels (Boros et al., 2016). The
non-selective cation channels transient receptor potential vanilloid 1
(TRPV1) and transient receptor potential ankyrin 1 (TRPA1) are mul-
timodal sensor proteins that sense temperature (cold or hot), the pre-
sence of exogenous or endogenous noxious chemicals and acidic pH
(Nilius et al., 2012; Numazaki and Tominaga, 2004; Szallasi, 1994).
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Chemosensitive aﬀerent neurons innervate most somatic and visceral
organs and tissues (Jancsó et al., 1987) and express the TRPV1 (Nilius
et al., 2012) and the TRPA1 (Bodkin and Brain, 2011; Zygmunt and
Högestätt, 2014) receptors, which play crucial roles in nociceptive and
neurogenic vascular and inﬂammatory reactions (Dux et al., 2003;
Earley and Brayden, 2015; Eberhardt et al., 2014; Geppetti et al., 2008;
Gouin et al., 2017). Activated chemosensitive aﬀerent nerves transmit
nociceptive signals towards the central nervous system and con-
comitantly release neuropeptides, such as calcitonin gene-related pep-
tide (CGRP) and substance P (SP) from their peripheral terminals
leading to arterial vasodilatation, increase in vascular permeability and
degranulation of mast cells (Brain, 1997; Holzer, 1998; Jansen-Olesen
et al., 2014; Maggi, 1995). Since signiﬁcant proportions of TRPV1 and
TRPA1 expressing chemosensitive sensory neurons are peptidergic
(Aubdool and Brain, 2011), the demonstration of peptide mediated
vascular reactions and the quantitative measurement of the release of
CGRP are reliable functional indicators of the activation of this parti-
cular class of nociceptors.
Local regulatory functions induced by neuropeptides released from
chemosensitive aﬀerents contribute also to protective mechanisms in
peripheral tissues (Kashem et al., 2015; Russell et al., 2014). Preclinical
experiments indicate that CGRP released from cardiac chemosensitive
aﬀerents is protective against adriamycin-induced cardiomyopathy
(Ferdinandy et al., 1997; Katona et al., 2004; Shi et al., 2011). Recent
observations from our laboratory have revealed profound structural and
functional changes in cutaneous chemosensitive nociceptors following
systemic adriamycin treatment. Adriamycin impaired both the sensory
aﬀerent function of chemosensitive nociceptors and the local eﬀerent
functions mediated by the release of neuropeptides (Boros et al., 2016;
Katona et al., 2004). Testing peripheral neurogenic vascular reactions
seems to be a useful tool to predict possible risks of adriamycin-induced
impairments of organ function. Since adriamycin-induced changes in
sensory functions develop prior to the manifestation of its cardiotoxic
eﬀect, they may also signalize upcoming cardiac injury (Boros et al.,
2016).
The mechanisms of adriamycin-induced pathophysiological changes
aﬀecting sensory and vascular functions are not fully understood. The
susceptibility of the diﬀerent compartments of the primary sensory
neuron to adriamycin appears to be diverse, too; nociceptor endings
seem to be more aﬀected than the rest of the neuron. In the skin,
adriamycin treatment decreases the density of epidermal nerve ﬁbers
while leaving the density and distribution of subepidermal nerve ﬁbers
apparently normal (Boros et al., 2016). Adriamycin seems to impair
also the contractility of vascular smooth muscle, probably by oxidative
stress modifying protein functions (Murata et al., 2001).
The present experiments were initiated in an attempt to reveal
adriamycin-induced changes in vascular and sensory eﬀector functions
of dural chemosensitive aﬀerent nerves in a well-established animal
model of meningeal nociception. Morphological and functional traits of
trigeminal aﬀerents innervating meningeal tissues in rats have already
been extensively studied in our laboratory (Dux et al., 2009, 2016a;
Marics et al., 2016). These studies have revealed that a substantial
proportion of dural aﬀerent nerves are capsaicin-sensitive, contain
CGRP and express the nociceptive ion channels TRPV1 and TRPA1 (Dux
et al., 2017; Dux et al., 2016b). Therefore, in the present study changes
in meningeal blood ﬂow and CGRP release were measured in control
and adriamycin-treated rats upon dural applications of speciﬁc agonists
of TRPV1 and TRPA1 in an open cranial window model. Changes in
TRPV1 protein content of trigeminal ganglia, expression and distribu-
tion of TRPV1 receptor immunoreactivity, CGRP immunoreactivity and
immunoreactivity of vascular CGRP receptor components in the dura
mater were also determined.
2. Methods
2.1. Animals
The experiments were approved by the Ethical Committee for
Animal Care of the University of Szeged. Study procedures were carried
out in accordance with the Directive 2010/63/EU of the European
Parliament. All eﬀorts were made to minimize the number of animals
used and their suﬀering.
Adult male Wistar rats weighing 270–330 g were used. One group of
animals received a cumulative dose of 15mg/kg of adriamycin
(Doxorubicin, Pharmacia Italia, Italy) by intravenous injection of
2.5 mg/kg of the drug three times a week for 2 weeks (Tong et al.,
1991). Control rats received equivalent amounts of the vehicle (saline).
All experiments were performed 2–7 days after cessation of the treat-
ment.
2.2. In vivo measurement of meningeal blood ﬂow
Control and adriamycin-treated animals were anesthetized with
thiopental sodium (100mg/kg, i.p. Insera Arzneimittel GmbH Freiburg,
Germany). The animals were tracheotomized and breathed sponta-
neously. Systemic blood pressure was recorded with a pressure trans-
ducer connected to a cannula inserted into the femoral artery. The body
temperature was monitored with a thermoprobe inserted into the
rectum and was held at 37–37.5 °C by a heating pad. For the mea-
surement of meningeal blood ﬂow, a cranial window was prepared
according to Kurosawa et al. (1995). The head of the animal was sta-
bilized in a stereotaxic frame, the scalp was incised in the midline and
the parietal bone was exposed on one side. A cranial window was
drilled into the parietal bone to expose the underlying dura mater.
Blood ﬂow was recorded with a needle-type probe of a laser Doppler
ﬂowmeter (Perimed, Sweden) positioned over a branch of the middle
meningeal artery. Data on meningeal blood ﬂow and systemic blood
pressure were processed with the Perisoft program (Perimed, Sweden).
Stimulation of the dura mater was performed by repeated topical ap-
plications of capsaicin (100 nM), acrolein (300 μM) and CGRP (10 μM)
at a volume of 40 μl for 3min followed by repeated washouts with
synthetic interstitial ﬂuid (SIF, containing in mM: 135 NaCl, 5 KCl, 1
MgCl2, 5 CaCl2, 10 glucose and 10 Hepes, pH 7.4). During washout
periods the basal blood ﬂow was restored. The eﬀects of single hista-
mine (10 μM), acetylcholine (100 μM) and forskolin (100 μM) applica-
tions were also tested. All drugs were purchased from Sigma-Aldrich
Chemie Gmbh, Hungary. A stock solution of capsaicin (32mM) was
prepared with the aid of 6% ethanol and 8% Tween 80 in saline and was
further diluted with SIF. All the other drugs were dissolved in SIF im-
mediately before use. Basal blood ﬂow was determined as the mean
ﬂow during a 3min period prior to drug application. Percentage
changes in meningeal blood ﬂow in response to capsaicin, acrolein,
CGRP, histamine, acetylcholine and forskolin were determined as mean
ﬂow values within the 3min application period relative to the basal
ﬂow. At the end of the experiments, the animals were sacriﬁced by an
overdose of thiopental sodium (200mg/kg, i.p.).
2.3. Ex vivo measurement of CGRP release
Measurement of the release of CGRP from dural aﬀerents was per-
formed by the method of Ebersberger et al. (1999). Control and
adriamycin-treated animals were deeply anesthetized with thiopental
sodium (200mg/kg, i.p.) and decapitated. After removal of the skin and
muscles, the skull was divided into halves along the midline and the
cerebral hemispheres were removed. The skull preparations were wa-
shed with carbogen-gassed SIF at room temperature for 30min and
then mounted in a humid chamber at 37 °C. The cranial fossae were
ﬁlled with 300 μl of carbogen-gassed SIF solution. Samples of the su-
perfusate were collected at periods of 5min by carefully removing the
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content of the skull halves with a pipette. Control samples were taken to
determine basal CGRP release then the dura was stimulated with re-
peated applications of capsaicin at 100 nM or acrolein at 300 μM.
Capsaicin and acrolein were applied three times separated by washout
periods with SIF. The CGRP releasing eﬀect of KCl (60mM) application
was also measured and compared with basal CGRP release. 100 μl of
samples diluted with 25 μl of enzyme-linked immunoassay (EIA) buﬀer
were placed into Eppendorf cups and immediately frozen at−70 °C for
subsequent analysis. The EIA method was used for measurement of
CGRP concentration (Bertin Pharma, France). The CGRP concentrations
of the superfusates were expressed in pg/ml. Changes induced in CGRP
release by capsaicin, acrolein and KCl were expressed as percentage
changes relative to the basal release.
2.4. Measurement of TRPV1 protein content in the trigeminal ganglion
Control and adriamycin-treated animals were deeply anesthetized
with thiopental sodium (200mg/kg, i.p.) and decapitated. After re-
moval of the skin and muscles, the skull was divided into halves along
the midline. The trigeminal ganglia were cut out, homogenized in
phosphate buﬀered saline and stored overnight at −20 °C. Two freeze-
thaw cycles were performed before centrifuging the homogenates at
4 °C for 5min at 5g. The supernatants were removed and frozen at
−70 °C for subsequent analysis. EIA method was used for the de-
termination of TRPV1 protein in tissue samples (Aviva Systems Biology,
USA). The TRPV1 concentration was expressed in pg/mg tissue.
2.5. Immunohistochemistry
The distribution of TRPV1- and CGRP-immunoreactive nerve ﬁbers
as well as CGRP receptor component protein- (RCP) and receptor ac-
tivity modifying protein (RAMP1)-immunoreactivities were studied in
dural whole mount preparations of control and adriamycin-treated rats
not used for in vivo blood ﬂow recordings or ex vivo CGRP release ex-
periments previously. Animals were anesthetized deeply with thio-
pental sodium (200mg/kg, i.p.) and perfused transcardially with phy-
siological saline followed by 4% paraformaldehyde in phosphate buﬀer
(pH 7.4). The skin and muscles of the skull were removed and the skull
was divided into halves along the sagittal suture. After removing the
brain, samples of the dura mater containing branches of the middle
meningeal artery were cut out, postﬁxed for 2 h in the same ﬁxative and
processed for staining with the indirect immunoﬂuorescence technique
using a rabbit polyclonal antiserum raised against the TRPV1 receptor
(1:500, Alomone Laboratories, Israel) in combination with a mono-
clonal mouse anti-CGRP antibody (1:500, Sigma-Aldrich, Germany).
IgGs labeled with Cy3 and DyLight 488 were used as secondary anti-
bodies (both 1:500, Jackson Immunoresearch Laboratories, USA).
CGRP receptor components RCP and RAMP1 were visualized using
mouse antiserum against RCP in combination with goat anti-RAMP1
(both 1:50, Santa Cruz Biotechnology, USA) primary and corresponding
secondary antibodies labeled with Alexa 555 and Alexa 488 (both
1:500, Molecular Probes, USA). Whole mount preparations of the dura
mater were examined under a confocal ﬂuorescence microscope (ZEISS
LSM 700, Germany).
2.6. Statistics
All values were expressed as means± SEM. Statistical analysis of
the data was performed using Statistica 13 (StatSoft, Tulsa, OK, USA).
In all groups normality was tested by the Shapiro-Wilk test. According
to the distribution of data the Student's t-test or the Wilcoxon test was
used. ANOVA with repeated measurements and Fisher's least signiﬁcant
diﬀerence test were used to analyze the consecutive measurements of
CGRP levels and blood ﬂow increases induced by repeated applications
of capsaicin, acrolein and CGRP. A probability level of p < 0.05 was
regarded as statistically signiﬁcant.
3. Results
3.1. Adriamycin-treatment impairs meningeal blood ﬂow upon TRPV1 and
TRPA1 receptor activation
In all experiments blood ﬂow was recorded from topographically
identical segments of the middle meningeal artery distant from visible
cortical blood vessels. The basal ﬂow values were between 200 and 500
perfusion units (PU) in control and adriamycin-treated rats. Topical
application of capsaicin (100 nM) in control rats was followed by a
signiﬁcant increase (28.6 ± 7.9%, n= 8) in meningeal blood ﬂow,
while in adriamycin-treated animals this response was weaker
(11 ± 3%, n=14). Capsaicin-induced increases in meningeal blood
ﬂow were reproducible in control animals, separated by washout per-
iods; the second and third applications of capsaicin increased me-
ningeal blood ﬂow by 30.3 ± 4 and 21.5 ± 3.4%, respectively. In
adriamycin-treated animals the responses to further capsaicin applica-
tions were almost completely abolished (2.6 ± 1.8 and 1 ± 0.6%;
Fig. 1A).
Topical application of acrolein at 300 μM had similar eﬀects. In
control animals three consecutive applications increased meningeal
blood ﬂow by 14.4 ± 2.4, 13.3 ± 3.7 and 8.9 ± 2.5% (n=9), re-
spectively. These increases in blood ﬂow were signiﬁcantly reduced in
Fig. 1. Eﬀect of repeated applications of capsaicin (100 nM, A) acrolein
(300 μM, B) and CGRP (10 μM, C) on meningeal blood ﬂow. *: statistically
diﬀerent from the basal ﬂow, #: statistically diﬀerent from the control, ‡: sta-
tistically diﬀerent from the eﬀect of the ﬁrst application.
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adriamycin-treated animals during all three consecutive applications
(4.1 ± 1.1, 2.6 ± 1.3 and 1.4 ± 1.8%; n=14; Fig. 1B).
CGRP-induced blood ﬂow increases were also reduced in adria-
mycin-treated animals, while repeated applications did not show a
decrement. Flow increases following CGRP at 10 μM were 20.3 ± 5.3,
21.8 ± 3.9 and 24.7 ± 5.3% (n=15) in control and 9.8 ± 1.6,
10 ± 1.9 and 8.6 ± 1.8% (n=17) in adriamycin-treated animals
(Fig. 1C).
In the two groups of animals no signiﬁcant diﬀerences in meningeal
blood ﬂow responses were seen following single topical applications of
histamine, acetylcholine or forskolin: they were in control vs. adria-
mycin-treated animals 21.3 ± 3.9 (n=10) vs. 22.3 ± 4.6% (n= 16)
after histamine, 15.8 ± 3.7 (n=12) vs. 16.9 ± 4.5% (n= 14) after
acetylcholine and 22 ± 8 (n=10) vs. 22.9 ± 9.8% (n= 10) after
forskolin applications (Fig. 2).
Systemic blood pressure of adriamycin-treated animals was slightly
below the values measured in controls: 98 ± 12 vs. 84 ± 10mmHg in
control vs. adriamycin-treated animals. Drugs administered topically to
the dura mater did in no case inﬂuence systemic blood pressure.
3.2. Adriamycin treatment modiﬁes CGRP release from meningeal aﬀerents
induced by TRPV1 and TRPA1 receptor activation or depolarizing KCl
Basal release of CGRP measured in the ex vivo dura mater pre-
paration was 13 ± 2.7 pg/ml in control and 20 ± 1.9 pg/ml in
adriamycin-treated rats, indicating a slight but not signiﬁcant
(p=0.054) increase in spontaneous basal CGRP release in adriamycin-
treated animals.
In control rats capsaicin at a concentration of 100 nM induced sig-
niﬁcant increases in CGRP release which were not signiﬁcantly dif-
ferent upon repeated administrations (294.2 ± 51.6, 229.5 ± 56.7
and 251.4 ± 101.4%; n= 7). In adriamycin-treated animals (n= 9)
the ﬁrst capsaicin application induced a signiﬁcantly higher increase in
CGRP release, which was 564.1 ± 71.2% of the basal release, while
further capsaicin-applications failed to increase the release:
117.1 ± 19.9 and 80.1 ± 12.5% at the second and third applications
of capsaicin (Fig. 3A).
In control rats (n= 6) TRPA1 receptor activation by acrolein at
300 μM increased CGRP release to 277.2 ± 25.9, 361.9 ± 50.6 and
385.6 ± 83.3% of the basal release at the three consecutive applica-
tions. While in adriamycin-treated animals CGRP-releasing eﬀect of the
ﬁrst acrolein application was comparable to that of the control
(273.9 ± 56.2% of the basal release, n= 6), the second and third
applications of acrolein induced only moderate increases in CGRP
release (162.5 ± 40.3 and 189.1 ± 56.8% of basal release, respec-
tively, Fig. 3B).
Depolarisation of meningeal aﬀerents by KCl (60mM) increased
CGRP release to 141.2 ± 24% (n= 7) and 189.3 ± 29% (n= 9) in
control and adriamycin-treated animals, respectively. The diﬀerence
between adriamycin-treated and control rats was not signiﬁcant
(p= 0.241).
3.3. Adriamycin-treatment decreases TRPV1 protein content in the
trigeminal ganglion
TRPV1 protein content of trigeminal ganglia obtained from control
rats was 6.25 ± 2.7 pg/mg tissue (n=10). Adriamycin-treatment re-
duced TRPV1 expression to 4 ± 0.5 pg/mg (n=11), although this
diﬀerence did not reach statistical signiﬁcance (p=0.147).
3.4. Adriamycin-treatment does not alter TRPV1- and CGRP-
immunoreactivity but modiﬁes immunohistochemical staining of CGRP
receptor components in the dura mater
In the dura mater of control and adriamycin-treated animals TRPV1-
and CGRP-immunoreactive nerve ﬁbers were distributed over the
whole supratentorial dura mater. TRPV1- and CGRP-immunoreactive
nerves were seen running in nerve bundles parallel with branches of the
middle meningeal artery. Single axons were also found in regions dis-
tant from larger blood vessels. CGRP was colocalized with TRPV1 in
most of these nerve ﬁbers. No obvious diﬀerence in the density and
distribution of TRPV1- and CGRP-immunoreactive aﬀerents was seen in
dura mater preparations of control (Fig. 4A) and adriamycin-treated
Fig. 2. Eﬀects of dural applications of histamine (10 μM), acetycholine
(100 μM) and forskolin (100 μM) on meningeal blood ﬂow. *: statistically dif-
ferent from the basal ﬂow.
Fig. 3. Capsaicin- (100 nM, A) and acrolein- (300 μM, B) induced release of
CGRP from meningeal aﬀerents. CGRP release is expressed as percentage
change relative to the basal release. *: statistically diﬀerent from the basal re-
lease, #: statistically diﬀerent from the control.
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animals (Fig. 4C).
In control animals the CGRP receptor component proteins RCP and
RAMP1 were colocalized in the wall of meningeal arteries and veins
(Fig. 4B). In dura samples of adriamycin-treated animals RAMP1-im-
munoreactivity was present, but no RCP-immunoreactive structures
could be identiﬁed in the wall of meningeal blood vessels (Fig. 4D).
4. Discussion
The present experiments aimed to study adriamycin-induced
changes in meningeal sensory nerve functions. The study revealed a
marked impairment of neurogenic blood ﬂow increase resulting from a
reduced release of vasodilator neuropeptides in the dura mater upon
noxious stimulation. The increase in blood ﬂow is an indirect measure
of the vasodilator response following the activation of the nociceptive
ion channels TRPV1 and TRPA1 expressed in chemosensitive dural af-
ferents, which seems to be reduced in adriamycin-treated rats.
Diminished responses were even more obvious after repeated stimula-
tion. The predominance of CGRP release from sensory nerve ﬁbers in
mediating these vasodilator responses is well established (Brain et al.,
1985; Kurosawa et al., 1995; Yisarakun et al., 2015). Accordingly, in an
established ex vivo dura mater preparation, CGRP release was directly
determined. In control rats capsaicin and acrolein, speciﬁc agonists
acting at TRPV1 and TRPA1 receptors, respectively, elicited re-
producible releases of CGRP of largely similar magnitudes. In dura
mater preparations obtained from rats treated with adriamycin, a
strikingly diﬀerent pattern of CGRP release appeared at repetitive
measurements, i.e. CGRP release was impaired only after the second
and third stimulation period with capsaicin or acrolein, respectively. In
adriamycin-treated dural specimens there was even an increase in in-
itial CGRP release after capsaicin application compared to control rats.
This is an unexpected ﬁnding, since the capsaicin-induced meningeal
vasodilator response, which is mainly mediated by CGRP, was markedly
attenuated in adriamycin-treated animals from the beginning. We
cannot explain the exact mechanism of the disparate changes observed
in the vasodilator response and the CGRP release but the following
considerations may be taken into account.
An intracellular/intraterminal increase in calcium ion concentration
is essential for the release of peptides from sensory nerves. Calcium
inﬂux is caused by the activation of transient receptor potential ion
channels, such as the TRPV1 and the TRPA1 channels, and possibly also
by opening of other ion channels which are permeable to calcium.
Hence, calcium inﬂux and its regulation are of crucial importance in the
mechanisms contributing to the control of peptide release from sensory
nerves. It is tempting to suggest that adriamycin-induced changes in
calcium inﬂux through the nociceptor membrane inﬂuence neuropep-
tide release. This assumption is supported by previous observations
showing that administration of adriamycin increased calcium inﬂux in
HeLa cells (Dasdia et al., 1979), and similarly calcium inﬂux may be
increased in sensory nerves of adriamycin-treated rats, resulting in in-
creased peptide release. Subsequent decreases in CGRP release even
beyond control levels may result from a reduced peptide content of
sensory nerves due to the excessive ﬁrst response upon capsaicin ad-
ministration. Reduced vasodilator capacity was even more obvious
after repeated stimulation of TRPV1 and TRPA1 receptors.
These observations prompted us to examine possible alterations in
vascular functions that may lead to impaired vasodilatation upon CGRP
release in adriamycin-treated animals. We tested the eﬀects of diﬀerent
vasodilator agents applied directly onto the dura mater. We measured
the blood ﬂow increasing eﬀects of histamine, acetylcholine and, in
particular, exogenous CGRP. Blood ﬂow increases induced by these
drugs are independent of the functional condition of meningeal nerves,
since they act directly on receptors localized on endothelial and/or
smooth muscle cells of dural blood vessels (Brunt et al., 2015; Dux
et al., 2002; Holzer, 1998). Histamine- and acetylcholine-induced va-
sodilatations were unaltered in adriamycin-treated animals while the
blood ﬂow increasing eﬀect of CGRP was reduced to about half of that
measured in control animals. The apparent similarity of histamine- and
acetylcholine-induced vasodilator responses in control and in adria-
mycin-treated animals suggests that damage to vascular smooth muscle
is unlikely to be responsible for the decreased vasodilatation to CGRP.
Although earlier observations indicated apoptotic and necrotic changes
in vascular smooth muscle after chronic exposure to adriamycin
(Murata et al., 2001), our functional results did not suggest a general-
ized impairment of vascular contractility. In our study we also tested
the integrity of intracellular mechanisms involved in CGRP-induced
vasodilatation. In adriamycin-treated rats they seemed to be preserved;
forskolin, activating adenylyl cyclase and increasing intracellular levels
of cAMP (Kanse et al., 1991) elicited similar increases in blood ﬂow in
both groups of animals.
Immunohistochemistry revealed a loss of CGRP receptor component
RCP-staining in arterial and venous dural blood vessels of adriamycin-
treated animals. The CGRP receptor is a multimer made up of a G-
protein-coupled receptor called calcitonin-like receptor (CLR), a small
transmembrane protein RAMP1 and a cytoplasmic protein RCP (Evans
et al., 2000). RCP is considered to enhance receptor coupling to the G-
protein signaling machinery. RCP protein expression seems to correlate
with CGRP eﬃcacy in vivo, suggesting its crucial role in the regulation
of CGRP signaling (Dickerson, 2013). RCP protein staining was un-
detectable in dura samples of adriamycin-treated animals indicating a
signiﬁcant change in protein structure resulting in a loss of im-
munohistochemical staining and an impairment of CGRP binding of the
receptor complex.
Our data indicate multiple but selective impairments of receptor
function in the trigeminovascular system after adriamycin treatment.
Altered TRPV1 and TRPA1 receptor functions in peripheral aﬀerents
results in a robust release of CGRP upon the ﬁrst application of the
corresponding agonist and in a reduced peptide release when the re-
ceptor is stimulated repeatedly. Taken together, these data indicate that
Fig. 4. Photomicrographs showing the distribution of TRPV1-, CGRP- (A, C)
and CGRP receptor component RCP- and RAMP1- (B,D) immunoreactivity in
the dura mater of control (A, B) and adriamycin-treated (C, D) rats. Scale bar on
C applies also for A; scale bar on D applies also for B. MMA: branch of the
middle meningeal artery, V: venous vessel.
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the markedly decreased vasodilator responses upon administration of
capsaicin and acrolein in adriamycin-pretreated rats may be explained
by alterations in CGRP signaling of the vascular smooth muscle. The
present ﬁndings also suggest that local regulatory/sensory eﬀerent
functions of chemosensitive aﬀerent nerves may be profoundly aﬀected
by the dynamics of neural peptide release.
While impairment of chemosensitive nociceptors was clearly sig-
nalised by decreased TRPV1 protein in the trigeminal ganglia of
adriamycin-treated animals, in the dura mater whole mount prepara-
tions of control and adriamycin-treated animals the density and dis-
tribution of TRPV1- and CGRP-immunoreactive nerves were apparently
similar. Despite the known limitations of immunohistochemistry to
detect moderate changes in protein content, our ﬁndings indicate that
reduction of capsaicin- (and probably also acrolein-) induced neuro-
genic sensory vasodilatation was brought about in the absence of ap-
parent changes in the distribution and localization of TRPV1- and
CGRP-immunoreactive dural aﬀerent nerves. We assume that changes
in TRPV1 and TRPA1 receptor functions may be similar after adria-
mycin-treatment, since the TRPA1 receptor is present on chemosensi-
tive neurons that also express TRPV1. Earlier observations in our la-
boratory indicated that pathophysiological conditions altering the
functions of chemosensitive aﬀerents may aﬀect the function of both
receptors (Marics et al., 2017; Marics et al., 2016).
A selective impairment of vascular contractility after adriamycin-
treatment has been reported earlier. In isolated arteries adriamycin-
treatment downregulated the expression of α1A adrenoceptors but left
the expression of endothelin A receptors unaltered (Murata et al.,
2001). Anthracycline-induced toxicity is believed to be related to the
generation of reactive oxygen species. Indeed, production of superoxide
radicals contributed to reduced expression of the α1A receptor of blood
vessels. Also receptors of chemosensitive aﬀerents can be targets of
reactive oxigen species. Both TRPV1- and TRPA1 receptors can be
modiﬁed by these mediators altering the gating properties of the ion
channels (Nishio et al., 2013; Ruan et al., 2014).
Besides functional changes of TRPV1 and TRPA1 receptors ex-
pressed on chemosensitive aﬀerents, earlier morphological observa-
tions in our laboratory also indicated loss of intraepidermal sensory
nerve endings but not subepidermal nerve plexuses after adriamycin
treatment (Boros et al., 2016). Although our results obtained from dura
mater preparations does not indicate loss of TRPV1- or CGRP-im-
munoreactivity in general, we cannot exclude the possibility of a similar
destruction of the most terminal compartments of sensory axons that,
however, are hardly detected in preparations of the dura mater due to
inherent diﬀerences in the organization of cutaneous and dural in-
nervation.
In conclusion, this study demonstrates an impairment of the noci-
ceptive function of peptidergic meningeal aﬀerents that results in di-
minished sensory neurogenic vasodilatation of meningeal blood vessels
in adriamycin-treated rats. The ﬁndings suggest that alterations in
neuronal CGRP release and changes in RCP receptor complex protein
expression may underlie the altered vascular responses. Adriamycin-
induced impairment of vascular functions may aﬀect sensory nerve-
mediated local tissue reactions and protective mechanisms, such as
neurogenic inﬂammation, which operate in the meninges.
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